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Studies in transgenic mice overexpressing amyloid precursor protein (APP) demonstrate impaired
autoregulation of cerebral blood flow (CBF) to changes in arterial pressure and suggest that
cerebrovascular dysfunction may be critically important in the development of pathological
Alzheimer’s disease (AD). Given the relevance of such a finding for guiding hypertension treatment
in the elderly, we assessed autoregulation in individuals with AD. Twenty persons aged 75±6 years
with very mild or mild symptomatic AD (Clinical Dementia Rating 0.5 or 1.0) underwent 15O-positron
emission tomography (PET) CBF measurements before and after mean arterial pressure (MAP)
was lowered from 107±13 to 92±9 mm Hg with intravenous nicardipine; 11C-PIB-PET imaging
and magnetic resonance imaging (MRI) were also obtained. There were no significant differences
in mean CBF before and after MAP reduction in the bilateral hemispheres (0.9±5.2 mL per 100 g
per minute, P = 0.4, 95% confidence interval (CI) =3.4 to 1.5), cortical borderzones (1.9±5.0 mL
per 100 g per minute, P = 0.10, 95% CI =4.3 to 0.4), regions of T2W-MRI-defined leukoaraiosis
(0.3±4.4 mL per 100 g per minute, P = 0.85, 95% CI =3.3 to 3.9), or regions of peak 11C-PIB uptake
(2.5±7.7 mL per 100 g per minute, P = 0.30, 95% CI =7.7 to 2.7). The absence of significant change
in CBF with a 10 to 15 mm Hg reduction in MAP within the normal autoregulatory range demonstrates
that there is neither a generalized nor local defect of autoregulation in AD.
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Introduction
Considerable evidence links cerebrovascular disease
with the development and expression of Alzheimer’s
disease (AD) (Farkas and Luiten, 2001; Jellinger, 2002).
Both share risk factors, such as hypertension, diabetes
mellitus, and hyperlipidemia, and ischemia may
trigger or worsen amyloid deposition (Kalaria, 2000;
Kudo et al, 2000). Furthermore, AD is associated with
nonatherosclerotic disease of small blood vessels and
infarcts with a predilection for cortical borderzones
(Suter et al, 2002). Periventricular white matter lesions,
presumably caused by incomplete ischemia, occur in
many individuals with AD (Brun and Englund, 1986;
Barber et al, 1999). Although the close association
of cerebrovascular disease with AD has been well
established by clinical studies, the pathophysiological
mechanism for this association has not.
Studies in transgenic mice overexpressing amyloid
precursor protein (APP) demonstrate globally impaired
autoregulation of cerebral blood flow (CBF) to changes
in arterial pressure, suggesting that cerebrovascular
dysfunction may be of critical importance in the
development of pathological AD (Zhang et al, 1997;
Niwa et al, 2002). If autoregulation is disordered,
moderate reductions in arterial pressure within the
normal autoregulatory range will lead to cerebral
hypoperfusion, favoring amyloid deposition in the brain
(Kalback et al, 2004). Globally impaired autoregulation
would produce ischemic damage predominantly in the
cortical borderzones and in periventricular white matter
(Matsushita et al, 1994), regions that are selectively
affected by ischemia in AD (Brun and Englund, 1986;
Suter et al, 2002). If autoregulation is intact, the causal
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relationship between b-amyloid and autoregulatory
dysfunction suggested by the APP mouse model would
need to be questioned.
Given the potential clinical importance that
knowledge of disordered cerebrovascular control
would have on management of hypertension in the
elderly, we performed a quantitative 15O-positron
emission tomography (PET) study to test the hypoth-
esis that individuals with clinically diagnosed AD
have impaired autoregulation of CBF.
Materials and methods
Participants
Participants were recruited from the Washington Univer-
sity Alzheimer’s Disease Research Center, which evaluates
individuals 60 years and older who are cognitively healthy
or demented. Details about the recruitment and assessment
methods for these individuals have been published (Berg
et al, 1998). Participants were eligible for inclusion in this
study if they were at least 60 years old, met the NINCDS-
ADRDA (National Institute of Neurological and Commu-
nicative Diseases and Stroke/Alzheimer’s Disease and
Related Disorders Association) criteria for a clinical
diagnosis of probable AD, and had a Clinical Dementia
Rating (CDR) (Morris, 1993) of 0.5 (very mild dementia) or
1 (mild dementia). Exclusion criteria included a mean
arterial pressure (MAP) of < 90 mm Hg (as measured by
arterial catheter before PET scanning), a history of stroke,
carotid artery stenosis > 70% (as determined by carotid
Doppler ultrasound performed before PET scanning), a
known allergy to calcium channel blockers, a known
history of hemodynamically significant aortic stenosis, or
contraindications for magnetic resonance imaging (MRI).
Informed consent with written documentation was
obtained from participants with cosignature from a legally
authorized representative. The study was approved by the
Human Research Protection Office and the Radioactive
Drug Research Committee of Washington University.
The following demographic and clinical data were
recorded: age, gender, race, age at dementia onset,
apolipoprotein E genotype, and a general medical history
including history of hypertension and use of antihyperten-
sive medications. The CDR, CDR sum of boxes (a more
quantitative representation of the CDR (Berg et al, 1992)),
and minimental state exam (Folstein et al, 1975) scores
from the most recent annual Alzheimer’s Disease Research
Center evaluation were recorded as well.
15O-Positron Emission Tomography Studies
All participants were studied on an ECAT EXACT HR 47
PET scanner (Siemens/CTI, Knoxville, TN, USA) located in
the Neurology-Neurosurgery Intensive Care Unit at Barnes-
Jewish Hospital. This scanner collects 47 contiguous
transverse slices encompassing an axial field of view of
15 cm. Spatial resolution is B4.3 mm full width at half
maximum at the center of the field of view. Antihyperten-
sive medications were held on the morning of the study.
All participants had a radial arterial catheter placed for
continuous measurement of arterial pressure and for
arterial blood sampling and a venous catheter placed in a
peripheral arm vein for administration of radiotracers and
nicardipine infusion. The PET scanner was calibrated for
conversion of PET counts to quantitative radiotracer
concentrations. Emission data were obtained in the 2D
mode (interslice septa extended) and reconstructed with
filtered backprojection with a ramp filter cutoff at the
Nyquist frequency using measured attenuation, scatter, and
randoms corrections.
The MAP (defined as 2/3 of diastolic plus 1/3 of systolic
blood pressure) and heart rate were monitored throughout
the entire PET study except for during acquisition of the
PET emission data when arterial blood was being sampled.
Partial pressure of carbon dioxide in the blood was
measured by arterial blood gas analysis immediately before
each emission scan.
The CBF was measured using an adaptation of the Kety
autoradiographic method with a 40-second emission scan
after rapid intravenous injection of 50 mCi of 15O-labeled
water (Raichle et al, 1983; Videen et al, 1987). Simulta-
neously with acquisition of the PET emission data, arterial
blood was sampled, and the arterial activity curve was
determined using a scintillation counter calibrated to the
same well counter as the PET scanner. The arterial time–
radioactivity curve recorded by the sampler was corrected
for delay and dispersion using previously determined
parameters. Baseline measurement of CBF was performed.
An intravenous infusion of nicardipine was then started
at 2.5 mg/h and titrated up to a maximum of 15 mg/h
to achieve a reduction in MAP by 10 to 15 mm Hg from
baseline. The MAP was held constant at this level for 7 to
10 minutes before repeat CBF measurement, sufficiently
long to permit the cerebrovascular responses to MAP
reduction to reach a new steady state (Kontos et al,
1978). A clinical assessment was performed at baseline
and after blood pressure lowering by asking participants
about symptoms of focal (lateralized weakness, numbness,
visual difficulty, or language problems) or general cerebral
hypoperfusion (lightheadedness, bilateral visual problems,
tinnitus) and testing immediate memory with digit span.
After completion of the repeat CBF measurement, nicardi-
pine infusion was stopped, allowing MAP to return
quickly to baseline.
11C-PIB-Positron Emission Tomography Studies
Amyloid imaging was performed using 11C-Pittsburgh
Compound B (11C-PIB) in 19 subjects (Mathis et al, 2003).
The PET scans were obtained using either a Siemens ECAT
EXACT HR 47 scanner or an ECAT EXACT HR + PET
scanner (Siemens/CTI) on a separate day from the 15O-PET
scan. All participants had a venous catheter placed in a
peripheral arm vein for administration of radiotracers.
Simultaneous with intravenous administration of 10 to
20 mCi of 11C-PIB, a 60-minute dynamic PET scan in 3D
mode (septa retracted) was initiated. Images were recon-
structed with filtered backprojection with a ramp filter
cutoff at the Nyquist frequency using measured attenua-
tion, model-based scatter, and randoms corrections.
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Magnetic Resonance Imaging Studies
All participants underwent brain MRI scanning using
Magnetom Sonata 1.5T or Trio 3T scanners (Siemens,
Erlangen, Germany). A midsagittal scout T1-weighted spin-
echo pulse sequence was used for positioning. A 3D MPRAGE
(Magnetization Prepared Rapid Acquisition Gradient Echo)
sequence (TR (repetition time) = 2400 milliseconds, TE (echo
time) = 3.16milliseconds, TI (inversion time) = 1000milli-
seconds, FA (Fractional Anisotropy) = 81, 1 1 1 mm3
voxels) produced a high-resolution T1-weighted image. T2-
weighted images were obtained using FLAIR (Fluid Attenu-
ated Inversion Recovery) (n= 6; TR= 10,000 milliseconds,
TE = 121 milliseconds, TI= 2500, FA =1501, 1 1 5 mm3),
TSE (Turbo Spin Echo) (n = 15; TR = 6000 milliseconds,
TE = 15milliseconds, FA = 1501, 1 1 2mm3), and a fast
spin-echo (n= 11; TR = 3200 milliseconds, TE = 455 millise-
conds, FA = 1201, 1 1 1mm3). A gradient echo-based echo
planar sequence was obtained in 13 subjects (TR =259milli-
seconds, TE =60milliseconds, FA = 601, 2 2 5mm3).
Data Analysis
The CBF images were aligned to MR anatomic images
(Woods et al, 1993), coregistered to a standard mean CBF
image in Talairach atlas space (Woods et al, 1992; Talairach
and Tournoux, 1998), and masked to exclude noncerebral
structures. Hemispheric CBF measurements were made
using a mask in Talairach space restricted to brain between
Z = 50 and Z =10, which corresponds to most of the
cerebrum between the superior sagittal sinus and trans-
verse sinus. As there was minimal change in partial
pressure of carbon dioxide in the blood between the two
CBF measurements (40.1±5.1 and 39.5±3.8 mm Hg,
P = 0.3), a CBF correction was not performed.
Composite 11C-PIB-PET images of PET counts were
created from dynamic scans collected 40 to 60 minutes
after PIB injection, filtered to a 3D resolution of 8 mm full
width at half maximum, normalized to cerebellar gray
matter, and coregistered with the two CBF scans for each
subject. An automated search routine using a 1-cm sphere
identified all PIB peaks separated by at least 16 mm (2
full width at half maximum) within the proscencephalon
of each subject. The 10% of all peaks with the highest PIB
deposition were identified. PIB uptake in these peaks was
at least 2.5 times that of cerebellar gray matter (Jack Jr et al,
2009). For 11 subjects in whom these peaks comprised at
least 10 mL, mean CBF values within the spheres were
computed before and after blood pressure reduction. The
remaining eight subjects had 0 to 3 peaks each sampling
< 2 mL, which was not large enough for meaningful CBF
comparisons.
The CBF measurements were also obtained in 1-cm
diameter spheres placed in the cortical borderzones as
identified on MRI (Carpenter et al, 1990). In each hemi-
sphere, one region was placed in the anterior borderzone
located in the depths of the superior frontal sulcus where
the pial anastomoses between the orbitofrontal branches of
the middle cerebral artery and the anterior frontal branches
of the anterior cerebral artery occur, and two were placed
in the posterior borderzone located in the inferior inter-
parietal sulcus where the pial anastomoses between the
temporal branches of the middle cerebral and posterior
cerebral arteries occur.
The CBF measurement within regions of leukoaraiosis
was restricted to the eight participants with Atherosclero-
sis Risk in Communities leukoaraiosis scores (Wong et al,
2002) of X5, as regions in participants with lower scores
would necessarily comprise narrow bands too small to
obtain meaningful PET data. Regions were defined by
thresholding only the larger aggregates of high-intensity
areas in T2-weighted MR images and then resampling
these regions in the coregistered PET.
The cerebral autoregulatory index was calculated as the
ratio of the percentage change in CBF and the correspond-
ing percentage change in MAP, where an autoregulatory
index of 0 would indicate perfect autoregulation.
The presence and size of radiographic cerebral infarcts
( < 1.5 or X1.5 cm) evident on T2-weighted MRI sequences
and the number and location of microbleeds (deep, lobar,
or infratentorial) evident on gradient-echo MRI sequences
were recorded. Microbleeds were defined as 2 to 10 mm
rounded areas of homogeneous signal loss on gradient echo
images. Symmetric areas of hypointensity in the globus
pallidus (considered to represent calcification or iron
deposition) and hypointensities in cortical sulci or in
areas of cortex near the inner table of the skull (considered
to represent blood vessels or signal averaging from adjacent
bone) were excluded. The degree of leukoaraiosis was
scored on T2-weighted MRI sequences using the 9-point
scale described in the Atherosclerosis Risk in Communities
study (Wong et al, 2002).
Mean cortical binding potential values for PIB were
calculated as the average of binding potentials in prefrontal
cortex, precuneus, laterotemporal cortex, and gyrus rectus
(Mintun et al, 2006).
The CBF before and after blood pressure reduction was
compared by paired t-test, and a confidence interval (CI)
for the difference in CBF was calculated. Statistical
analyses were performed with SPSS 17.0 for Windows
(SPSS, Inc, Chicago, IL, USA). The primary analysis was
for prosencephalic (bihemispheric) CBF at a type I error
rate of 5% (P < 0.05). Power and sample size calculations
used data from Tohgi et al on baseline CBF in gray and
white matter regions in AD, data from Niwa et al in
transgenic mice overexpressing APP for estimating the
expected differences in regional CBF, and data from our
previous study of autoregulation in acute intracerebral
hemorrhage to estimate variance (Tohgi et al, 1998; Powers
et al, 2001; Niwa et al, 2002). On the basis of the transgenic
mouse data, a 12.5-mm Hg reduction in MAP is expected to
produce a 13.8% reduction in CBF in severely impaired
autoregulation and a 9.8% reduction in moderately
impaired autoregulation. All other analyses were consid-
ered exploratory and not corrected for increased type I
error from multiple comparisons.
Results
Twenty-three individuals were enrolled in the study.
The PET scanning was not performed in two because
MAP as measured by arterial catheter was < 90 mm Hg.
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One was excluded due to technical difficulties during
the 15O-PET scan. Clinical and radiographic character-
istics of the remaining 20 participants are shown in
Table 1 and Supplementary Table 1.
Mean arterial pressure was lowered 14.6±
5.6 mm Hg (13.5%) from a baseline of 107.0±
12.6 mm Hg without clinical change or other adverse
event. There was a concomitant 12% increase in
heart rate (P = 0.005). One subject (13) with an
MAP of 144 mm Hg during the baseline study had a
> 30 mm Hg fall in MAP upon using a urinal after the
CBF measurement. Neurological status did not change.
There was no significant change in CBF within the
bilateral cerebral hemispheres (0.9±5.2 mL per
100 g per minute, P = 0.4, 95% CI =3.4 to 1.5), in
1-cm regions within the anterior and posterior
cortical borderzones (1.9±5.0 mL per 100 g per
minute, P = 0.10, 95% CI =4.3 to 0.4), in regions of
leukoaraiosis (0.3±4.4 mL per 100 g per minute,
P = 0.85, 95% CI =3.3 to 3.9), or in the upper 10% of
peak PIB uptake (2.5±7.7 mL per 100 g per minute,
P = 0.30, 95% CI =7.7 to 2.7) (Table 2; Supplemen-
tary Table II; Figure 1). Differences in CBF among the
four analyses are likely due to differences in the
fraction of gray matter in the regions of interest. The
bihemispheric autoregulatory index was 0.06±1.01.
Thus, for a 10% change in MAP, there was a 0.6%
change in CBF.
Discussion
In this study of 20 individuals with mild AD, we did
not find autoregulatory impairment globally or in
cortical borderzones, regions of leukoaraiosis, or
regions of high-PIB uptake with a 10 to 15 mm Hg
reduction in MAP within the normal autoregulatory
range. Our results suggest that impaired autoregula-
tion is unlikely to be of pathogenic importance in the
development of AD.
We targeted a blood pressure reduction sufficient
enough to determine if autoregulation is impaired
but not to a degree that it fell outside the normal
autoregulatory range. Strandgaard (1976) found that
the lower limit of autoregulation was 25 mm Hg
below resting blood pressure in normotensive and
20 mm Hg below in well-controlled hypertensive
individuals. Using a computerized method, Schmidt
et al (1990) reported smaller decreases of 13 mm Hg
for normotensive and 18 mm Hg for hypertensive
individuals before the lower limit was reached.
We achieved a blood pressure reduction of
13 mm Hg in our normotensive and 15 mm Hg in our
Table 1 Clinical and radiographic characteristics
Age, years 74.6±6.2
Sex, M/F 14/6
Clinical Dementia Rating (CDR) a
0.5 16
1 4
CDR sum of boxes score 3.0±1.6
Minimental state exam score 26.2±3.8




Participants with hypertension 15
Years of hypertension 12.8±9.7
Current antihypertensive medicationsb
ACE inhibitor 8
Calcium channel blocker 6
b-Blocker 5
Diuretic 3




Participants with infarcts 11
< 1.5 cm 11
X1.5 cm 5




Leukoaraiosis ARIC (Wong et al, 2002) score 3 (1–7)
MCBP for PIB 0.60±0.38
MCBPX0.18 17d
APOE, apolipoprotein E; ARIC, Atherosclerosis Risk in Communities;
MCBP, mean cortical binding potential; MRI, magnetic resonance imaging;
PET, positron emission tomography.
aRating based on clinical assessment performed 175±76 days before PET.
bIncludes seven taking a single agent, five on dual therapy, and three on triple
therapy.
cScoring possible only in 13 participants with gradient echo sequence
available.
dOf 19 with PIB scans.
Data are expressed as mean±s.d. or median (range).
Table 2 Change in mean arterial blood pressure (MAP) and cerebral blood flow (CBF)
MAP mm Hg gCBF mL per 100 g
per minute
BZ mL per 100 g
per minute
leuko mL per 100 g
per minute
PIB mL per 100 g
per minute
Baseline 107.0±12.6 43.5±11.1 42.0±11.3 20.9±7.2 58.8±16.0
Postnicardipine 92.3±9.1 42.5±9.7 40.0±9.9 20.6±7.0 56.2±17.4
% Changea 13.5%±3.3% 0.6%±12.8% 3.2%±12.1% 1.2%±22.0% 4.5%±12.8%
BZ, borderzone regions; g, global; leuko, regions of leukoaraiosis (differences computed in the eight subjects with ARIC leukoaraiosis scores (Wong et al, 2002)
of X5); PIB, regions of peak PIB uptake (differences computed in the 11 subjects in whom peaks comprised at least 10 mL).
aPercentage change calculated as the mean of the percent change in values for each subject.
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chronically hypertensive subjects. Had our subjects
behaved similarly to the transgenic mice overexpres-
sing APP, the 14.6 mm Hg reduction in MAP within
the normal autoregulatory range that we achieved
would have been expected to produce a 16.8%
reduction in CBF in severely impaired autoregula-
tion and a 11.5% reduction in moderately impaired
autoregulation (Niwa et al, 2002). Instead, we
observed only a nonsignificant 0.6% decrease in
hemispheric CBF in our subjects. In addition, the
autoregulatory index we determined is well within
the normal autoregulatory index range of 0 to 0.4
reported in other studies using various species and
protocols (Kawamura et al, 1975; Donegan et al,
1985; Jones et al, 2002). Although there was some
variability in the percentage change in CBF from
subject to subject, such variability in response to a
reduction in blood pressure is a known phenomenon
in normal animals (Jones et al, 2002). Both a para-
doxical rise in CBF as perfusion pressure is dropped
(hyperautoregulation) and a linear response of CBF
to perfusion pressure changes have been reported
within the control group of normal animals. Thus,
an aggregate autoregulation index from all subjects
provides the most meaningful data.
Our methodology has been demonstrated to be
sensitive enough to detect changes in CBF with
physiological manipulations in human subjects
(Diringer et al, 2000; Jost et al, 2005). Using
this method, we have observed clinically evident
autoregulatory dysfunction in the MAP range above
the lower limit but during induced moderate
hypotension (Powers et al, 2009). Had we found a
decrease in CBF with blood pressure reduction
within the normal autoregulatory range in this study,
data from normal control subjects would have been
important to ensure that the decrease was signifi-
cantly different from normal. However, we observed
< 1 mL per 100 g per minute change in CBF in our
subjects, which is clinically irrelevant whether
or not it differs from controls.
Before this study, comparable data on autoregula-
tion of CBF in patients with AD did not exist. Two
groups have reported preserved vascular reactivity
to changes in arterial CO2 in patients with AD
(Kuwabara et al, 1992; Nagata et al, 1997, 2002). As
CO2 reactivity and autoregulation may be dissociated
(Fieschi et al, 1968; Paulson et al, 1972), these
observations do not bear on the issue of autoregula-
tion. Passant et al (1996) measured cortical CBF with
Xenon-133 inhalation in 13 subjects with AD and
severe orthostatic hypotension. Although they report
no change in CBF, the results are difficult to
interpret. As the CBF measurement took place over
11 minutes and the blood pressure was fluctuating
during this period, it is not possible to obtain an
accurate CBF measurement with this steady state
technique. In addition, no CBF data from white
matter or deep gray matter structures can be obtained
with this technique.
We chose subjects in the early stages of AD (CDR
0.5 and 1) for this study. Even in the earliest stages,
histological criteria of AD are demonstrable in the
majority of individuals— > 90% of those who die
at the CDR 0.5 or 1 stage have neuropathological
AD (Storandt et al, 2006). All but two of the
19 participants who had PIB scans had elevated
PIB binding. In our previous work, we found that
participants with dementia of the Alzheimer type
typically showed mean cortical binding potential
Figure 1 Composite mean cerebral blood flow (CBF) difference image. Composite mean difference image of all 20 participants,
showing that the maximum mean decrease in CBF anywhere in the brain is < 0.1 mL per 100 g per minute or < 0.2%.
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values for PIB of X0.18 (Mintun et al, 2006), but that
PIB binding can be negligible even in individuals
with a CDR of 0.5 and pathologically proven AD
(Cairns et al, 2009). Explanations for a ‘negative’ PIB
scan include misdiagnosis in which the clinical
dementia is not due to AD and inability of PIB to
detect AD variants that are characterized predomi-
nantly by diffuse amyloid plaques. Our data do not
allow us to address whether autoregulatory impair-
ment occurs in the late stages of human AD, but this
information would have low clinical relevance as
intervention to prevent progression at this stage
would be of little value.
Because of the exclusion criterion of an
MAP < 90 mm Hg, the mean MAP of 107 mm Hg in
our participants was higher than normal and three
quarters of them had a history of hypertension.
Although chronic hypertension shifts the autoregu-
latory curve to higher pressures, it does not lengthen
the autoregulatory plateau and so would not be
expected to alter the interpretation of our negative
results. In fact, the autoregulatory plateau may
actually be shorter in some hypertensive individuals
(Strandgaard, 1983).
Evaluating the status of autoregulation is compli-
cated by the effects of antihypertensive agents on the
cerebral vasculature. We chose intravenous nicardi-
pine for this study because we have used it to
produce acute MAP reductions of 16 to 23 mm Hg in
patients with acute intracerebral hemorrhage and
ischemic stroke without any change in CBF (Powers
et al, 2001, 2009). Many of the participants in this
study were being treated with antihypertensive
agents, but none of the agents has been shown to
impair autoregulation with chronic use.
In conclusion, a reduction in arterial pressure
within the normal autoregulatory range in indivi-
duals with AD did not reduce CBF globally or in
cortical borderzones, regions of leukoaraiosis, or
regions of high-PIB uptake. Unlike in animal models
of AD, impaired autoregulation of CBF to changes in
arterial pressure is not present in early AD and is
therefore unlikely to be important in the develop-
ment of pathological AD in humans. Our data suggest
that the association between b-amyloid and auto-
regulatory dysfunction in the APP mouse model may
be an epiphenomenon that has no bearing on the
cerebrovascular consequences of human AD; thus
caution is warranted in applying this aspect of the
APP mouse model to human AD.
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